Analysed PRIME MEDICINE INC (PRME:NASDAQ) News Sources
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
18-06-2026
yahoo.com
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22-06-2026
yahoo.com
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
08-07-2026
biopharmadive.com
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
08-07-2026
yahoo.com
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
08-07-2026
stocktwits.com
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
15-07-2026
yahoo.com
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
23-07-2026
yahoo.com
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
30-07-2026
yahoo.com
What is the current price of PRIME MEDICINE INC (PRME:NASDAQ)?
The current price of PRIME MEDICINE INC (PRME:NASDAQ) is $3.68.
PRIME MEDICINE INC (PRME:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRIME MEDICINE INC (PRME:NASDAQ) since the previous trading day is $0.43.
PRIME MEDICINE INC (PRME:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRIME MEDICINE INC (PRME:NASDAQ) since the previous trading day is 13.2308%.
What is the most recent average sentiment score for PRIME MEDICINE INC (PRME:NASDAQ)?
The most recent average sentiment score for PRIME MEDICINE INC (PRME:NASDAQ) is 58 out of 100.
What is the most recent average sentiment for PRIME MEDICINE INC (PRME:NASDAQ)?
The most recent sentiment for PRIME MEDICINE INC (PRME:NASDAQ) is .
SEC-8K** Filing Available For PRIME MEDICINE INC (PRME:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.